Effectiveness of Treatment for Concussion-Related Convergence Insufficiency: The CONCUSS Study
Study Overview
The CONCUSS study is a clinical trial that aims to compare two treatment approaches for concussion-related convergence insufficiency (CONC-CI). It will evaluate:
- Immediate Office-Based Vergence/Accommodative Therapy with Movement (OBVAM)
- Delayed OBVAM (starting six weeks later)
The study will also explore how the timing of treatment and the number of therapy sessions (12 vs. 16) affect recovery.
Who is Involved?
The trial will enroll 100 participants aged 11-25 who have:
- A medically diagnosed concussion
- Persistent symptoms 4-24 weeks after injury
- Symptomatic convergence insufficiency
What Will Happen?
Participants will receive standard concussion care and be randomly assigned to one of the two treatment groups. After 7 weeks, their progress will be assessed based on:
- Near Point of Convergence (NPC)
- Positive Fusional Vergence (PFV)
- Symptom improvement
After this assessment, the delayed group will start their therapy sessions, while the immediate group will have additional sessions.
Key Features of the Study
- Clear definitions of conditions and outcomes
- Standardized diagnostic and treatment protocols
- Use of objective eye movement tracking and brain imaging
This study aims to establish best practices for treating CONC-CI and understand how OBVAM works.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, helps integrate clinical protocols and research into a user-friendly resource for healthcare providers.
Enhancing Healthcare Delivery
In today’s healthcare landscape, efficiency is vital. Our mobile apps facilitate:
- Scheduling
- Monitoring treatments
- Telemedicine services
This simplifies patient care and expands digital services.
Learn More
Discover how we can support your clinic in improving workflows and patient outcomes at aidevmd.com.
